You are here


7 million people receive record levels of lifesaving TB treatment but 3 million still miss out
More people received life-saving treatment for tuberculosis (TB) in 2018 than ever before, largely due to improved detection and diagnosis. Globally, 7 million people were diagnosed and treated for TB - up from 6.4 million in 2017 – enabling the world to meet one of the milestones towards the United Nations political declaration targets on TB.
Opinion: Approval of new TB drug lays bare crisis in TB research
Last week the United States Food and Drug Administration approved the drug pretomanid for use in combination with bedaquiline and linezolid “for treating a limited and specific population of adult patients with extensively drug resistant, treatment-intolerant or nonresponsive multidrug resistant pulmonary tuberculosis (TB)”.
New tuberculosis medicine studied in South Africa approved in United States
Despite the fact that often-deadly extensively drug-resistant tuberculosis (XDR-TB) is found in roughly 127 countries, up until now it has been treated with a ‘kitchen sink’ approach. Doctors, using their discretion, throw many often-toxic drugs into a lengthy treatment regimen – unsure if the combination will lead to a cure. XDR-TB is by definition resistant to many key tuberculosis medicines used today.
Is scaling up active case finding the missing piece in our TB response?
South Africa has one of the highest burdens of tuberculosis (TB) in the world. The World Health Organization (WHO) estimates that 322 000 people in South Africa had active TB disease in 2017, meaning they were presenting symptoms and could spread the TB bacteria. Approximately 60% of these people were also living with HIV. TB is the leading reported cause of death among people living with HIV and in South Africa overall (although models indicate that HIV still causes slightly more deaths). 
#HearMeToo is message for Women's Month
The Ministry for Women, Youth and Persons with Disabilities in the Presidency has dedicated this Women's Month to addressing economic empowerment, eradication of gender-based violence and elimination of pay gaps for equal work. Under the theme “25 Years of Democracy: Growing South Africa Together for Women's Emancipation”, the ministry launched the campaign yesterday in Pretoria. During the launch, Minister Maite Nkoana-Mashabane set the tone with the hashtag #HearMeToo.
Partnership between USAID TB South Africa Project and Next2People successfully pilots a collaboration intervention with general practitioners to increase TB diagnosis in OR Tambo district
USAID TB South Africa Project, in partnership with the organisation Next2People, is implementing an intervention to increase capacities of general practitioners (GPs) in OR Tambo district, Eastern Cape province, to identify symptoms of tuberculosis (TB) and increase rates of diagnosis and treatment among people who seek their services. The intervention was launched in December 2018 and Eastern Cape was selected in part because it has the second highest burden of TB by province in South Africa.
New method reveals how well TB antibiotics reach their targets
Scientists have developed a new technique that enables them to visualise how well antibiotics against tuberculosis (TB) reach their pathogenic targets inside human hosts. The findings, published in the journal Science, boost our understanding of how antibiotics work and could help guide the development of new antibiotics, which are much-needed in the battle against drug-resistance.
Men’s Health in South Africa
The purpose of Men’s Health Month is to heighten the awareness of preventable health problems and encourage early detection and treatment of disease among men and boys. This month gives health care providers, public policy makers, the media, and individuals an opportunity to encourage men and boys to seek regular medical advice and early treatment for disease and injury. 
NIH launches large TB prevention trial for people exposed to multidrug-resistant TB
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.